CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 202 enrolled
Drug / intervention
LY3556050 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04627038
NCT04627038Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain

Eli Lilly and Company·interventional·Posted Nov 13, 2020·Updated Nov 2, 2023

In Brief

A Phase 2 clinical trial evaluating LY3556050 and Placebo for Osteoarthritis. Completed, enrolled 202 participants across 40 sites in 2 countries.

Detailed Summary

This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 13, 2020
Enrollment StartNov 12, 2020
Primary CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.6 years ago

Interventions

LY3556050drug

LY3556050 Given orally

Placebodrug

Placebo Given orally